The SOLAR-1 trial found that adding alpelisib, a PI3Kα-specific inhibitor, provided a progression-free survival benefit and OS improvement in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer patients (31). This evidence concerns the gene NR4A1 and breast cancer.